Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Current Assets (2016 - 2025)

Seres Therapeutics' Current Assets history spans 11 years, with the latest figure at $51.5 million for Q3 2025.

  • For Q3 2025, Current Assets fell 29.35% year-over-year to $51.5 million; the TTM value through Sep 2025 reached $51.5 million, down 29.35%, while the annual FY2024 figure was $38.7 million, 77.95% down from the prior year.
  • Current Assets for Q3 2025 was $51.5 million at Seres Therapeutics, up from $48.7 million in the prior quarter.
  • Across five years, Current Assets topped out at $358.8 million in Q3 2021 and bottomed at $38.7 million in Q4 2024.
  • The 5-year median for Current Assets is $194.8 million (2022), against an average of $179.1 million.
  • The largest annual shift saw Current Assets soared 212.77% in 2021 before it plummeted 77.95% in 2024.
  • A 5-year view of Current Assets shows it stood at $303.6 million in 2021, then crashed by 35.85% to $194.8 million in 2022, then fell by 9.94% to $175.4 million in 2023, then tumbled by 77.95% to $38.7 million in 2024, then soared by 33.23% to $51.5 million in 2025.
  • Per Business Quant, the three most recent readings for MCRB's Current Assets are $51.5 million (Q3 2025), $48.7 million (Q2 2025), and $66.1 million (Q1 2025).